Jan 06, 2022 / 04:00PM GMT
Matthew Carlisle Sykes - Goldman Sachs Group, Inc., Research Division - Research Analyst
Good morning, good afternoon, everyone. I'm Matt Sykes, senior life science tools and diagnostics analyst at Goldman Sachs, and I have the pleasure of welcoming the team from Agilent here today, Mike McMullen, the CEO and President; and Bob McMahon, Senior VP and CFO. Mike, Bob, Happy New Year. Thanks for joining us.
Michael R. McMullen - Agilent Technologies, Inc. - CEO, President & Director
Matt, Happy New Year to you and your clients as well. And from Bob and I's perspective, it's real pleasure to be here. On the heels of our closing off is a record year for Agilent. As you may know, Matt, we added almost $1 billion of revenue in 2021, 15% core on top of a growth the prior year, 1% core, so it wasn't just an easy comparatory for us. All our business groups grew 10% or greater, operating margin up 200 basis points and EPS up 32%.
So -- and then specific to the fourth quarter, we entered 2022 with momentum. I sure we'll talk more about this, but when I say
Agilent Technologies Inc at Goldman Sachs Healthcare CEOs Unscripted Conference: A View from the Top (Virtual) Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers